These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Health insurance considerations for adolescent transplant recipients as they transition to adulthood. Willoughby LM; Fukami S; Bunnapradist S; Gavard JA; Lentine KL; Hardinger KL; Burroughs TE; Takemoto SK; Schnitzler MA Pediatr Transplant; 2007 Mar; 11(2):127-31. PubMed ID: 17300489 [TBL] [Abstract][Full Text] [Related]
3. Income-related disparities in kidney transplant graft failures are eliminated by Medicare's immunosuppression coverage. Woodward RS; Page TF; Soares R; Schnitzler MA; Lentine KL; Brennan DC Am J Transplant; 2008 Dec; 8(12):2636-46. PubMed ID: 19032227 [TBL] [Abstract][Full Text] [Related]
4. Medicare-approved drug discount cards and renal transplant patients: how much can these cards reduce prescription costs? Chisholm MA; Marshall J; Smith KE; Garrett CJ; Turner JC Clin Transplant; 2005 Jun; 19(3):357-63. PubMed ID: 15877798 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach. Jürgensen JS; Arns W; Hass B Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139 [TBL] [Abstract][Full Text] [Related]
6. Associations of renal function at 1-year after kidney transplantation with subsequent return to dialysis, mortality, and healthcare costs. Schnitzler MA; Johnston K; Axelrod D; Gheorghian A; Lentine KL Transplantation; 2011 Jun; 91(12):1347-56. PubMed ID: 21659964 [TBL] [Abstract][Full Text] [Related]
10. Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States. Tanriover B; Stone PW; Mohan S; Cohen DJ; Gaston RS Clin J Am Soc Nephrol; 2013 Jul; 8(7):1258-66. PubMed ID: 23559679 [TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era. Kadatz M; Gill JS; Gill J; Formica RN; Klarenbach S J Am Soc Nephrol; 2020 Jan; 31(1):218-228. PubMed ID: 31704739 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppression of the elderly kidney transplant recipient. Danovitch GM; Gill J; Bunnapradist S Transplantation; 2007 Aug; 84(3):285-91. PubMed ID: 17700150 [TBL] [Abstract][Full Text] [Related]
13. The 12th Annual Report of the North American Pediatric Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Seikaly M; Ho PL; Emmett L; Tejani A Pediatr Transplant; 2001 Jun; 5(3):215-31. PubMed ID: 11422826 [TBL] [Abstract][Full Text] [Related]
14. Duration of end-stage renal disease and kidney transplant outcome. Goldfarb-Rumyantzev A; Hurdle JF; Scandling J; Wang Z; Baird B; Barenbaum L; Cheung AK Nephrol Dial Transplant; 2005 Jan; 20(1):167-75. PubMed ID: 15546892 [TBL] [Abstract][Full Text] [Related]
15. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients. Lewis RL; Canafax DM; Pettit KG; DiCesare J; Kaniecki DJ; Arnold RJ; Roberts MS Transplant Proc; 1996 Aug; 28(4):2214-7. PubMed ID: 8769203 [No Abstract] [Full Text] [Related]
16. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Yen EF; Hardinger K; Brennan DC; Woodward RS; Desai NM; Crippin JS; Gage BF; Schnitzler MA Am J Transplant; 2004 Oct; 4(10):1703-8. PubMed ID: 15367228 [TBL] [Abstract][Full Text] [Related]